Edwards Lifesciences

Edwards Lifesciences Share Price Undervalued by 12.6%: DCF Analysis

Edwards Lifesciences to Host Earnings Call on February 10, 2026

爱德华兹生命科学

Edwards Lifesciences Experiences MACD Death Cross, Bearish Marubozu on 15-Minute Chart

Edwards Lifesciences' ROE Fuels Long-Term Growth Amidst Recent Stock Decline.

Edwards Lifesciences MACD Death Cross triggers Bollinger Bands Narrowing on 15-minute chart.

Catalyst<ul> <li>Most analysts rate EW Buy or Strong Buy, showing broad institutional optimism.</li></ul>Risk<ul> <li>Technical indicators show that the market is in a weak state and need to pay attention to the risk of decline.</li> <li>Bearish signals are obviously dominant (5 bearish vs 0 bullish) according to recent technical signals.</li></ul>

Key Factors

Edwards Lifesciences (EW) shares rose 0.78% on February 6, 2026, amid pre-earnings optimism with $510 million in trading volume. Edwards Lifesciences (EW) shares fell 2.09% on February 5, 2026, with $550 million in trading volume amid mixed market conditions. A discounted cash flow analysis indicates Edwards Lifesciences (EW) shares are undervalued by 12.6%, with an intrinsic value of $89.38 per share.

EW News